Azithromycin for Child Survival in Niger II

Last updated: June 14, 2024
Sponsor: University of California, San Francisco
Overall Status: Active - Recruiting

Phase

4

Condition

N/A

Treatment

Azithromycin for Oral Suspension

Clinical Study ID

NCT06358872
23-39839
  • Ages 1-59
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR). The World Health Organization (WHO) guidelines for this intervention specify that implementation must be accompanied by continued monitoring of mortality and AMR. Niger is expanding the azithromycin MDA program nationwide. To establish monitoring of mortality and AMR as part of this program as well as to leverage the infrastructure to evaluate other child health interventions, AVENIR II is designed as an adaptive platform trial with monitoring and re-randomization every 2 years.

Eligibility Criteria

Inclusion

Inclusion Criteria:

CSI-level for mortality and AMR monitoring:

  • Located in a region participating in the program

  • Designated as rural by local study team

  • Selected for participation in monitoring activities

  • Safe and accessible for study teams

  • Verbal approval from community leaders

Individual level for mortality monitoring:

  • Residing in the catchment area of an eligible CSI

  • Selected for participation in monitoring activities

  • Female

  • Age between 12 and 55 years old

  • Verbal approval from participant

Individual-level for AMR monitoring:

  • Residing in the catchment area of an eligible CSI

  • Selected for participation in monitoring activities

  • Age between 1 and 59 months old

  • Verbal approval from a caregiver or guardian

Exclusion

Exclusion Criteria:

At the community-level:

  • Designated as urban by local study team

  • Inaccessible or unsafe for study team

At the individual-level:

  • Known allergy to macrolides

Study Design

Total Participants: 3300000
Treatment Group(s): 1
Primary Treatment: Azithromycin for Oral Suspension
Phase: 4
Study Start date:
April 29, 2024
Estimated Completion Date:
April 29, 2028

Study Description

AVENIR II is a cluster-randomized adaptive platform trial designed to evaluate community health interventions in Niger. The initial focus is to monitor under-5 mortality and antimicrobial resistance as the azithromycin MDA for child survival program expands in Niger, with the following specific aims:

  1. Mortality.

    1. To conduct surveillance of mortality over time compared to the Sustainable Development Goal targets for under-5 mortality reduction. As this intervention is not intended to continue indefinitely, surveillance against a target is needed to determine when to stop.

    2. To continue to evaluate the effectiveness of azithromycin MDA to reduce under-5 mortality. Given the risk of AMR, the effectiveness of the intervention over time is needed to fully weigh the risks against the benefits.

  2. Antimicrobial Resistance. To determine the impact of azithromycin MDA on AMR in population- and clinic-based samples.

Connect with a study center

  • Program National de Santé Oculaire

    Niamey,
    Niger

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.